Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.43
+0.07 (0.24%)
At close: Mar 6, 2026, 4:00 PM EST
29.75
+0.32 (1.09%)
After-hours: Mar 6, 2026, 5:12 PM EST
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Celldex Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $44.5, which forecasts a 51.21% increase in the stock price over the next year. The lowest target is $24 and the highest is $68.
Price Target: $44.5 (+51.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $30 → $34 | Hold | Maintains | $30 → $34 | +15.53% | Mar 2, 2026 |
| Stifel | Stifel | Strong Buy Reiterates $58 → $68 | Strong Buy | Reiterates | $58 → $68 | +131.06% | Feb 26, 2026 |
| Barclays | Barclays | Sell Maintains $21 → $24 | Sell | Maintains | $21 → $24 | -18.45% | Dec 17, 2025 |
| Barclays | Barclays | Sell Maintains $25 → $21 | Sell | Maintains | $25 → $21 | -28.64% | Nov 11, 2025 |
| Mizuho | Mizuho | Buy Initiates $48 | Buy | Initiates | $48 | +63.10% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
3.05M
from 1.55M
Increased by 97.61%
Revenue Next Year
10.75M
from 3.05M
Increased by 252.01%
EPS This Year
-4.76
from -3.90
EPS Next Year
-4.79
from -4.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 12.6M | 36.6M | |||
| Avg | 3.1M | 10.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 715.5% | 1,100.2% | |||
| Avg | 97.6% | 252.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.86 | -3.47 | |||
| Avg | -4.76 | -4.79 | |||
| Low | -5.17 | -5.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.